Browsing Tag
ASCO 2024
6 posts
RemeGen’s RC88 shows promising results in Phase I/II study for advanced solid tumors
RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase…
Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing…
Lilly announces promising updates on olomorasib in KRAS G12C-mutant cancers at ASCO 2024
Eli Lilly and Company (Lilly, NYSE: LLY) has released updated data from its ongoing Phase 1/2 clinical trial…
Rakuten Medical announces promising interim results from photoimmunotherapy study at ASCO 2024
Rakuten Medical, Inc., a pioneer in biotechnology focusing on precision, cell-targeting photoimmunotherapy, unveiled updated interim results from its…
Theratechnologies to unveil promising long-term efficacy for sudocetaxel zendusortide in solid tumors at ASCO 2024
Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX), a biopharmaceutical leader focused on innovative therapy developments, has revealed Phase 1…
Zentalis Pharmaceuticals reports promising results from Phase 1 trial of azenosertib, gemcitabine combo
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a trailblazer in developing small molecule therapeutics for cancer, has released the final…